No effect modification of influenza virus vaccine effectiveness by age or chronic condition was observed in the 2010/11 to 2017/18 seasons.

Purpose Most European influenza vaccine strategies target individuals at higher risk of complications, which include, among others, individuals aged ≥65 years and with chronic conditions. These individuals not only have a high‐risk of post‐infection complications but also could have lower capacity of acquiring adequate vaccine‐induced protection. As such, chronic conditions and age could modify the effect of vaccines. This study aimed at assessing the potential effect modification of influenza vaccine effectiveness (IVE) by age and chronic conditions. Methods: We used eight‐season data from the Portuguese vaccine effectiveness study. Every season, physicians at primary care units recruited patients with influenza‐like illness. Clinical data and swabs were collected for Reverse Transverse Polymerase Chain Reaction (RT‐PCR) detection of influenza. Trivalent inactivated IVE was estimated as 1 – odds ratio (OR) of being vaccinated in cases (RT‐PCR positive for influenza) versus negative controls. ORs were obtained using a multivariable conditional logistic regression model, paired by week of onset within each season. Confounders were assessed by designing a specific causal diagram. Age (< 65 or ≥65 years) and chronic conditions (diabetes, cardiovascular disease, chronic renal disease, chronic hepatic disease, obesity, chronic respiratory disease, and congenital or acquired immunodeficiency) were studied as effect modifiers by including an interaction term in the regression models. Significance was established at 5%. Results: Point estimates indicate a higher IVE in the chronic condition strata compared to that in the no chronic condition strata. Regarding age, different results were obtained considering the virus type and (sub)type. When comparing the ≥65 years with the <65 years of age strata, we observed a higher IVE against A(H1N1)pdm09, an equal IVE against A(H3N2) and a lower IVE against B virus. However, all interaction terms were statistically insignificant, and this may be due to a small sample size. Conclusion: The potential effect modification of age or chronic condition was not observed within our study. [ABSTRACT FROM AUTHOR]